Nizamieva, Aygul
Frolova, Sheida
Slotvitsky, Mihail
Kovalenko, Sandaara
Tsvelaya, Valeriya
Nikitina, Anna
Sergeevichev, David
Agladze, Konstantin
Funding for this research was provided by:
Moscow Institute of Physics and Technology
M. F. Vladimirsky Moscow Regional Research Clinical Institute
Ministry of Health of the Russian Federation
Article History
Received: 21 July 2022
Accepted: 7 November 2022
First Online: 18 November 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki and the Guide for the Care and Use of Laboratory Animals, published by the United States National Institutes of Health (Publication No. 85–23, revised 1996), and was approved by the Moscow Institute of Physics and Technology Life Science Center Provisional Animal Care and Research Procedures Committee, Protocol #A2-2012–09-02.The cell line m34Sk3 is provided by the “E. Meshalkin National Medical Research Center” of the Ministry of Health of the Russian Federation and handling approved by the Institute of Circulation Pathology Ethics Committee (#27, March 21, 2013). All experiments and procedures were performed in accordance with principles for human experimentation as defined in the 1964 Declaration of Helsinki and its later amendments and were approved by the Scientific Council of the MIPT Life Science Center.
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of all figures, tables, and data included in this article.
: The authors declare no competing interests.